Holly Springs leaders gathered at Seqirus earlier today to celebrate groundbreaking on a $140 million expansion of the cell-based influenza vaccine producer’s manufacturing facility in the Holly Springs Business Park. The expansion will bring the plant to more than 475,000 square feet at the 185-acre site and will support a growing demand for cell-based influenza vaccines.
The expansion is expected to generate 120 jobs over the next three years, adding to the current workforce of 550 full-time employees. Construction of the facility is expected to be completed by April 2020.
“In 2006, no one could have imagined the economic impact this would bring,” said Holly Springs Mayor Dick Sears at the event. “We are very proud of our partnership and look forward to an exciting future together.”
“Today commemorates an important milestone for both our local community in North Carolina and our nation’s protection against severe illness and death caused by influenza,” said U.S. Senator Richard Burr, who spoke at the event. “I am proud to support the development of innovative influenza vaccine technologies to help protect the American people.”
The Holly Springs manufacturing facility was purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to combat pandemic influenza threats. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. This public-private partnership is the first in the world to establish cell-based technology as a highly scalable method of production.